Traditional H1 receptor antagonists are a mainstay of drug therapy for the allergic state, but cause numerous discomforting side effects which often hinder compliance. Newer H1 antagonists, including astemizole and terfenadine, appear remarkably free of central side effects and may provide a therapeutic breakthrough for clinicians. H2 antagonists have revolutionized drug therapy for hypersecretory states. Ranitidine appears to have fewer side effects than cimetidine at this stage in its utilization history, but has not been used as extensively. Other antisecretory agents of promise include some tri-cyclic antidepressants, prostaglandin derivatives, and potassium-hydrogen ATPase inhibitors. Newer histamine-release inhibitors (ketotifen, oxatimide e.g.) are effective orally and offer better patient compliance.
Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.